Skip to main content
Log in

Esomeprazole

  • Adis New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

▴ Esomeprazole, a new proton pump inhibitor, is the S-isomer of omeprazole and is the first such inhibitor to be developed as a single isomer.

▴ Esomeprazole provided better control of intragastric pH than omeprazole, lansoprazole and pantoprazole in trials conducted in patients with gastro-oesophageal reflux disease (GORD) or healthy volunteers (n = 20 to 115).

▴ In 2 large randomised, double-blind multicentre trials esomeprazole 20 and/or 40mg for 8 weeks produced higher healing rates of erosive oesophagitis and better symptom control than omeprazole 20mg in patients with GORD.

▴ Esomeprazole 10, 20 or 40mg once daily for 6 months maintained healing versus placebo (p < 0.001) in patients with endoscopically confirmed healed erosive oesophagitis in 2 large randomised, double-blind multicentre trials.

▴ Similarly, symptom-driven on-demand use of esomeprazole effectively controlled symptoms of GORD (heartburn) for 6 months in 2 large placebo-controlled trials.

▴ Esomeprazole-based triple therapy for 7 days was as effective for eradication of Helicobacter pylori as longer omeprazole-based therapy in 2 randomised double-blind trials including about 450 patients each. Endoscopically confirmed ulcer healing 4 weeks after treatment initiation was reported in about 90% of patients with active duodenal ulcer in both treatment groups.

▴ Esomeprazole-based triple therapy for 10 days was more effective than esomeprazole plus clarithromycin for eradication of H. pylori in 233 patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management —the Genval Workshop Report. Gut 1999; 44 Suppl. 2: S1-S16

    Google Scholar 

  2. DeVault KR, Castell DO, The Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999 Jun; 94: 1434–42

    Article  PubMed  CAS  Google Scholar 

  3. Crawley JA, Hamelin B, Gallagher E. How satisfied are chronic heartburn sufferers with the results they get from prescription strength heartburn medications [abstract]? Gastroenterology 2000; 118: A210

    Article  Google Scholar 

  4. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control versus omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000 Jul. In press

  5. Hassan-Alin M, Niazi M, Röhss K, et al. Esomeprazole, the S-isomer of omeprazole, is optically stable in humans [abstract]. Gastroenterology 2000; 118 Suppl. 2: A1244-5

    Google Scholar 

  6. Astra Zeneca. Summary of Product Characteristics. Nexium tablets 20 mg and 40 mg. Mölndal, Sweden: AstraZeneca, 2000. (Data on file)

    Google Scholar 

  7. Langtry HD, Wilde MI. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs. Drugs 1998; 56(3): 447–86

    Article  PubMed  CAS  Google Scholar 

  8. Röhss K, Lundin C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than omeprazole 40 mg [abstract]. Presented at the XXXIInd Nordic Meeting of Gastroenterology; 2000 Jun 18–21: Göteborg, Sweden

  9. Wilder-Smith C, Röhss K, Lundin C, et al. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A22

    Article  Google Scholar 

  10. Röhss K, Claar-Nilsson C, Rydholm H, et al. Esomeprazole 40 mg provides more effective acid control than lanzoprazole 30 mg [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A20

    Article  Google Scholar 

  11. Lind T, Kylebäck A, Rydberg L, et al. Esomeprazole provides improved acid control vs omeprazole in patients with symptoms of GERD [poster]. Presented at Digestive Disease Week; 2000 May 21–24: San Diego, California

  12. Bell NJV, Burget D, Howden CW, et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992; 51 Suppl. 1: 59–67

    Article  PubMed  Google Scholar 

  13. Maton P, Vakil NB, Hwang C, et al. Safety and efficacy of long-term treatment with esomeprazole in patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A19

    Article  Google Scholar 

  14. Andersson T, Rohss K, Hassan-Alin M, et al. Pharmacokinetics (PK) and dose-response relationship of esomeprazole (E) [abstract no. 5550]. Gastroenterology 2000; 118 (4) Suppl. 2: A1210

    Google Scholar 

  15. Andersson T, Bredberg E, Sunzel M, et al. Pharmacokinetics (PK) and effect on pentagastrin stimulated peak acid output (POA) of omeprazole (O) and its 2 optical isomers, S-omeprazole/esomeprazole (E) and R-omeprazole (R-O) [abstract no. 5551]. Gastroenterology 2000; 118 (4) Suppl. 2: 1210

    Google Scholar 

  16. Hassan-Alin M, Röhss K, Andersson T, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [abstract no. 328]. Gastroenterology 2000; 118(4): A16

    Article  Google Scholar 

  17. Junghard O, Hassan-Alin M, Hasselgren G. The effect of AUC and Cmax of esomeprazole on acid secretion and intragastric pH [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A17

    Article  Google Scholar 

  18. Hasselgren G, Hassan-Alin M, Andersson T, et al. Pharmacokinetics of esomeprazole are not affected by age: an assessment in the elderly [abstract]. Gastroenterology 2000; 118 Suppl. 2: A1245

    Google Scholar 

  19. Sjövall H, Hagman I, Holmberg J, et al. Pharmacokinetics of esomeprazole in patients with liver cirrhosis [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A21

    Article  Google Scholar 

  20. Kahrilas PJ, Falk G, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomised controlled trial. Aliment Pharmacol Ther 2000; In press

  21. Richter JE, Kahrilas PJ, Hwang C, et al. Esomeprazole is superior to omeprazole for healing of erosive esophagitis (EE) in GERD patients [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A20

    Article  Google Scholar 

  22. Johnson DA, Benjamin SB, Whipple J, et al. Efficacy and safety of esomeprazole as maintenance therapy in GERD patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A17

    Article  Google Scholar 

  23. Vakil NB, Shaker R, Hwang C, et al. Esomeprazole is effective as maintenance therapy in GERD patients with healed erosive esophagitis (EE) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A22

    Article  Google Scholar 

  24. Talley NJ, Venables TL, Green JBR, et al. Esomeprazole 40mg and 20mg is efficacious in the lomg-term management of patients with endoscopy-negative GERD: a placebo-controlled trial of on-demand therapy for 6 months [abstract]. Gastroenterology 2000; 118: A658

    Article  Google Scholar 

  25. Talley NJ, Lauritsen K, Tunturi-Hihnala H, et al. Esomeprazole 20mg maintains symptom control in endoscopy-negative GERD: a randomized placebo-controlled trial of on-demand therapy for 6 months [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A21

    Article  Google Scholar 

  26. Veldhuyzen van Zanten SJO, Lauritsen K, Delchier J-C, et al. 7-day triple therapy with esomeprazole, amoxicillin and clarithromycin for H. pylori (Hp) eradication in duodenal ulcer (DU) disease [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A503

    Google Scholar 

  27. Tulassay Z, Kryszewski A, Ditc P, et al. 7-day treatment with esomeprazole-based triple therapy eradicates H. pylori (Hp) and heals patients with DU disease [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A502

    Article  Google Scholar 

  28. The European Helicobacter Pylori Study Group (EHPSG). Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. Gut 1997; 41: 8–13

    Article  Google Scholar 

  29. Fennerty MB, Laine LA, Sugg J, et al. Esomeprazole-based triple therapy is more effective than dual therapy for eradication of H. pylori (Hp) [abstract and poster presented at Digestive Disease Week; 2000 May 21–24: San Diego, California]. Gastroenterology 2000; 118: A495

    Article  Google Scholar 

  30. Genta RM, Magner DJ, D’Amico D, et al. Safety of long-term treatment with a new PPI, esomeprazole in GERD patients [abstract no. 326]. Gastroenterology 2000; 118(4): A16

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Caroline M. Spencer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Spencer, C.M., Faulds, D. Esomeprazole. Drugs 60, 321–329 (2000). https://doi.org/10.2165/00003495-200060020-00006

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200060020-00006

Keywords

Navigation